MA55910A - Immunothérapies ciblant cd123 - Google Patents
Immunothérapies ciblant cd123Info
- Publication number
- MA55910A MA55910A MA055910A MA55910A MA55910A MA 55910 A MA55910 A MA 55910A MA 055910 A MA055910 A MA 055910A MA 55910 A MA55910 A MA 55910A MA 55910 A MA55910 A MA 55910A
- Authority
- MA
- Morocco
- Prior art keywords
- immunotherapies targeting
- immunotherapies
- targeting
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4214—Receptors for cytokines
- A61K40/4217—Receptors for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962845307P | 2019-05-08 | 2019-05-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA55910A true MA55910A (fr) | 2022-03-16 |
Family
ID=73051377
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA055910A MA55910A (fr) | 2019-05-08 | 2020-05-07 | Immunothérapies ciblant cd123 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220315638A1 (fr) |
| EP (1) | EP3966338A1 (fr) |
| JP (1) | JP2022531718A (fr) |
| CN (1) | CN114402079A (fr) |
| AU (1) | AU2020267559A1 (fr) |
| CA (1) | CA3139512A1 (fr) |
| MA (1) | MA55910A (fr) |
| WO (1) | WO2020227481A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113366479A (zh) | 2018-12-14 | 2021-09-07 | 蓝鸟生物公司 | 二聚化剂调节的免疫受体复合物 |
| BR112021020999A2 (pt) | 2019-05-04 | 2021-12-14 | Inhibrx Inc | Polipeptídeos de ligação à clec12a e usos dos mesmos |
| EP3966249A4 (fr) | 2019-05-08 | 2023-05-10 | 2seventy bio, Inc. | Immunothérapies ciblant cll -1 |
| CN119585438A (zh) | 2022-05-26 | 2025-03-07 | 再生元制药公司 | 用于维持慢病毒载体的组合物及其用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6543626B2 (ja) * | 2013-07-29 | 2019-07-10 | ブルーバード バイオ, インコーポレイテッド | 多部分シグナル伝達タンパク質およびその使用 |
| CA2995632C (fr) * | 2015-08-24 | 2023-02-07 | Cellectis | Recepteurs d'antigenes chimeriques ayant des fonctions integrees pouvant etre controlees |
| LT3383425T (lt) * | 2015-12-04 | 2020-10-12 | Boehringer Ingelheim International Gmbh | Biparatopiniai polipeptidai, veikiantys antagonistiškai wnt signaliniam keliui vėžinėse ląstelėse |
-
2020
- 2020-05-07 CA CA3139512A patent/CA3139512A1/fr active Pending
- 2020-05-07 WO PCT/US2020/031794 patent/WO2020227481A1/fr not_active Ceased
- 2020-05-07 EP EP20802729.2A patent/EP3966338A1/fr not_active Withdrawn
- 2020-05-07 JP JP2021566151A patent/JP2022531718A/ja active Pending
- 2020-05-07 AU AU2020267559A patent/AU2020267559A1/en not_active Withdrawn
- 2020-05-07 MA MA055910A patent/MA55910A/fr unknown
- 2020-05-07 US US17/608,739 patent/US20220315638A1/en not_active Abandoned
- 2020-05-07 CN CN202080048002.1A patent/CN114402079A/zh not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020227481A1 (fr) | 2020-11-12 |
| AU2020267559A1 (en) | 2022-01-06 |
| CN114402079A (zh) | 2022-04-26 |
| EP3966338A1 (fr) | 2022-03-16 |
| JP2022531718A (ja) | 2022-07-08 |
| US20220315638A1 (en) | 2022-10-06 |
| CA3139512A1 (fr) | 2020-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA42395S (uk) | Футляр | |
| EP3818843A4 (fr) | Cigarette | |
| DE102020112518B8 (de) | Toner | |
| EP3818842A4 (fr) | Cigarette | |
| EP3555124C0 (fr) | Tcr nyeso | |
| EP3781060A4 (fr) | Cryosonde | |
| EP3845661A4 (fr) | Pyrrolysyl-arnt synthétase | |
| EP3818840A4 (fr) | Cigarette | |
| MA55905A (fr) | Immunothérapies ciblant cll -1 | |
| EP3784463A4 (fr) | Fluorosulfones | |
| JP1643514S (ja) | 電子タバコ用カートリッジ | |
| MA55910A (fr) | Immunothérapies ciblant cd123 | |
| DE112019006314A5 (de) | Förderanordnung | |
| EP3745904C0 (fr) | Poignée de bâton | |
| EP3899155A4 (fr) | Raccord amélioré | |
| JP1643249S (ja) | 電子タバコ用カートリッジ | |
| EP3721129A4 (fr) | Cryosphère | |
| PL3829776T3 (pl) | Komora flotacyjna | |
| DE112019006342A5 (de) | Förderanordnung | |
| EP3904110A4 (fr) | Cartouche | |
| EP3904107A4 (fr) | Cartouche | |
| JP1650005S (ja) | 電子タバコ用カートリッジ | |
| DK3587968T3 (da) | Fluidsystem | |
| PL3829774T3 (pl) | Komora flotacyjna | |
| PL3880011T3 (pl) | Sposób |